Marc Voigt | Chief Executive Officer
Immutep Ltd | Australia

Marc Voigt, Chief Executive Officer, Immutep Ltd

Marc has more than 18 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Prima’s Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net. IPO AG, a publicly-listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds.


Phar-East Day One @ 12:00

The next big immune checkpoint: LAG-3

  •     The potential of LAG-3 in immune oncology and autoimmune diseases
  •     Combination therapy as a key therapeutic strategy in oncology
  •     Collaborations as a path to success in global drug development

back to speakers